Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Effect of Aged Garlic Extract on Atherosclerosis

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
EstadoTerminado
Patrocinadores
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Colaboradores
Wakunaga Pharmaceutical Co., Ltd.

Palabras clave

Abstracto

The investigators will be assessing the effect of Aged Garlic Extract on the coronary arteries. The investigators will enroll patients in a double blind study, where half the patients will receive placebo, and have the patients undergo a series of tests of plaque (CT scan of the heart, carotid ultrasound) and follow the patients on the drug or placebo and then repeat the tests and blood work at the end of one year. The investigators will assess if being on aged garlic extract adds any benefit to plaque in the coronary or neck arteries. The investigators will also assess the effect of aged garlic extract on markers of inflammation. Patients will receive free drug, free testing and be compensated, and learn more about their heart and neck arteries. if successful, more patients can use this drug to benefit their health. The harms include the radiation from the CT scan and the medication, which has mild side effects.

Descripción

The investigators will be assessing the effect of Aged Garlic Extract on the coronary arteries. The investigators will enroll patients in a double blind study, where half the patients will receive placebo, and have the patients undergo a series of tests of plaque (CT scan of the heart, carotid ultrasound) and follow the patients on the drug or placebo and then repeat the tests and blood work at the end of one year. The investigators will assess if being on aged garlic extract adds any benefit to plaque in the coronary or neck arteries. The investigators will also assess the effect of aged garlic extract on markers of inflammation. Patients will receive free drug, free testing and be compensated, and learn more about their heart and neck arteries. if successful, more patients can use this drug to benefit their health. The harms include the radiation from the CT scan and the medication, which has mild side effects. The study will perform advanced CT angiography at baseline and follow up along with carotid intimal media thickness testing, to see if plaque is slowed down by Aged Garlic Extract

fechas

Verificado por última vez: 02/28/2017
Primero enviado: 02/13/2012
Inscripción estimada enviada: 02/15/2012
Publicado por primera vez: 02/16/2012
Última actualización enviada: 03/08/2017
Última actualización publicada: 04/19/2017
Fecha de los primeros resultados enviados: 02/19/2015
Fecha de los primeros resultados de CC enviados: 03/18/2015
Fecha de los primeros resultados publicados: 04/02/2015
Fecha de inicio real del estudio: 04/30/2012
Fecha estimada de finalización primaria: 11/30/2014
Fecha estimada de finalización del estudio: 11/30/2014

Condición o enfermedad

Metabolic Syndrome

Intervención / tratamiento

Drug: Aged Garlic Extract

Drug: Sugar pill

Fase

Fase 4

Grupos de brazos

BrazoIntervención / tratamiento
Placebo Comparator: Sugar pill
placebo
Drug: Sugar pill
placebo
Active Comparator: Aged Garlic Extract
2400 mg of aged garlic extract
Drug: Aged Garlic Extract
2400 mg a day

Criterio de elegibilidad

Edades elegibles para estudiar 40 Years A 40 Years
Sexos elegibles para estudiarAll
Acepta voluntarios saludablessi
Criterios

Inclusion Criteria

- Age 40-65 years

- Framingham risk score 6-20%, and at least 2 components of the metabolic syndrome as defined by ATP III Clinical Identification of the Metabolic Syndrome (including impaired fasting glucose > 110 mg/dl, treated hypertension or SBP > 130 or DBP > 85 mm Hg, plasma triglycerides > 150 mg/dl, HDL cholesterol < 35 mg/dl for men or < 40 mg/dl for women, abdominal obesity as defined as waist > 40 in for men, > 35 in for women)

- Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them

- Subjects should be stable on their concomitant medications for at least 26 weeks prior to randomization

- Calcium Score > 20 at baseline

- Subjects who agree to refrain from other anti-glycemic agent Exclusion Criteria

- A contraindication to AGE including: known hypersensitivity to drug.

- Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study

- Weight in excess of 300 pounds

- Bleeding disorder

- History of known coronary artery disease, myocardial infarction, stroke or life-threatening arrhythmia within the prior six months

- NYHA Class II- IV heart failure

- History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy

- Serum creatinine > 1.4 mg/dl

- Diabetes Mellitus

- Triglycerides > 400 at visit 1

- Drug or alcohol abuse, or current intake of more than 14 standard drinks per week

- Concurrent enrollment in another placebo-controlled trial

- Partial ileal bypass or known gastrointestinal disease limiting drug absorption

- Current diabetes or intake of anti-diabetic or other prohibited drug

- Current tobacco use

- Current use of anticoagulants (except for anti-platelet agents)

- Renal failure

- History of hypertensive encephalopathy or cerebrovascular accident

- Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI

Salir

Medidas de resultado primarias

1. CT Angiography Plaque [baseline to 1 year]

we will measure low attenuation plaque at baseline (in volume) and then again at 1 year. we will assess if there is a reduction in low attenuation plaque volume (percent change from baseline), defined as [followup-baseline]/baseline x100%. Baseline was time zero, followup CT scan was 1 year.

Medidas de resultado secundarias

1. Coronary Calcium [1 year]

Agatston score is a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an unenhanced low-dose CT scan. The calculation is based on the weighted density score given to the highest attenuation value (HU) multiplied by area of the calcification speck. The grading of coronary artery disease (based on total calcium score) is as follows: no evidence of CAD: 0 calcium score, minimal: 1-10, mild: 11-100, moderate: 101-400, and severe: >400

Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge